Table 4.
Fluorescence-activated cell sorting.
| Healthy donors (n = 500) | Achalasia (all) (n = 189) | Type I (n = 59) | Type II (n = 123) | Type III (n = 7) | |
|---|---|---|---|---|---|
| Circulating CD4+ T cell subpopulations | |||||
| CD4+/CD161-/IL-22+ (%) mean ± SD | 2.3 ± 0.1 | 8.5 ± 0.4 | 9.4 ± 0.7 | 7.9 ± 0.5 | 10 ± 2 |
| Median | 2.51 | 7.74 | 9.05 | 6.98 | 11.7 |
| Range | 0.35–3.90 | 2.75–19.9 | 5.79–19.9 | 2.75–15.6 | 6.93–13.0 |
| CD4+/CD161+/IL-17A+ (%) mean ± SD | 2.0 ± 0.1 | 7.6 ± 0.3 | 7.9 ± 0.5 | 7.3 ± 0.3 | 9.8 ± 0.8 |
| Median | 2.12 | 7.61 | 8.11 | 7.55 | 10.5 |
| Range | 0.41–3.47 | 2.68–14.8 | 2.68–13.5 | 2.95–14.8 | 8.05–10.7 |
| CD4+/CD25-/IL-4+ (%) mean ± SD | 2.0 ± 0.1 | 7.1 ± 0.3 | 6.6 ± 0.4 | 7.5 ± 0.5 | 5.7 ± 1.7 |
| Median | 2.08 | 6.41 | 6.33 | 6.54 | 5.92 |
| Range | 0.23–3.93 | 2.72–17.1 | 2.81–10.2 | 2.90–17.1 | 2.72–8.58 |
| CD4+/CD25-/IFN-+ (%) mean ± SD | 2.0 ± 0.1 | 6.9 ± 0.3 | 6.8 ± 0.5 | 6.9 ± 0.4 | 7 ± 3 |
| Median | 1.91 | 6.17 | 6.31 | 6.12 | 4.9 |
| Range | 0.29–4.65 | 2.23–13.4 | 2.44–11.1 | 2.99–13.4 | 2.23–12.8 |
| CD4+/CD25hi/Foxp3+ (%) mean ± SD | 6.5 ± 0.3 | 9.2 ± 0.3 | 9.5 ± 0.4 | 8.9 ± 0.4 | 10 ± 1 |
| Median | 6.83 | 8.9 | 9.08 | 8.87 | 10.1 |
| Range | 1.34–9.20 | 1.36–15.6 | 6.26–13.5 | 1.36–15.6 | 8.07–12.3 |
| CD19+/CD24+/CD38+/IL-10+ (%) mean ± SD | 8 ± 3 | 10 ± 3 | 9 ± 3 | 10 ± 3 | 16 ± 1 |
| Median | 8.4 | 10.8 | 9.3 | 11 | 15.8 |
| Range | 2.0–13.7 | 4.1–17.4 | 4.1–14.0 | 4.1–15.9 | 14.6–17.4 |
| CD123+/CD196+/IDO+ (%) mean ± SD | 16.9 ± 0.6 | 37± 1 | 32 ± 2 | 38 ± 2 | 46 ± 2 |
| Median | 17.2 | 36 | 31.6 | 38.1 | 45.7 |
| Range | 6.79–28.1 | 16.8–62.0 | 21.5–47.4 | 16.8–62.0 | 43.1–49.3 |